Immune dysregulation in sepsis

Clinical Pediatric Emergency Medicine

Volumn 15, Issue 2, 2014, Pages 163-168

  Malakooti, Marcelo ^a   Kelleher, Michael ^a   Wald, Eric ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Compensatory anti inflammatory response syndrome (CARS); Immune system; Immunoparalysis; Sepsis; Systemic inflammatory response syndrome (SIRS)

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; CYTOKINE; DROTRECOGIN; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; PROCALCITONIN;

ADAPTIVE IMMUNITY; ARTICLE; BLOOD CLOTTING; COMPENSATORY ANTIINFLAMMATORY RESPONSE SYNDROME; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOPARALYSIS; IMMUNOPATHOLOGY; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE; MONOCYTE; NONHUMAN; POLYMORPHONUCLEAR CELL; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84904381833     PISSN: 15228401     EISSN: 15582310     Source Type: Journal    
DOI: 10.1016/j.cpem.2014.04.002     Document Type: Article

References (42)

1. Bone R.C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996, 24:1125-1128.
2. Cinel I., Opal S.M. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009, 37:291-304.
3. Landelle C., Lepape A., Francais A., et al. Nosocomial infection after septic shock among intensive care unit patients. Infect Control Hosp Epidemiol 2008, 29:1054-1065.
4. Hotchkiss R.S., Monneret G., Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13:260-268.
5. Cavaillon J.M., Adib-Conquy M. Monocytes/macrophages and sepsis. Crit Care Med 2005, 33(12 Suppl):S506-S509.
6. Cavaillon J.M., Adrie C., Fitting C., et al. Reprogramming of circulatory cells in sepsis and SIRS. J Endotoxin Res 2005, 11:311-320.
7. Hotchkiss R.S., Monneret G., Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013, 13:862-874.
8. Giamarellos-Bourboulis E.J., Scaglione F. International Journal of Antimicrobial Agents. Presentations from the 4th European Conference on Bloodstream Infections Introduction. Int J Antimicrob Agents 2010, 36(Suppl 2):S1.
9. Monneret G., Venet F., Pachot A., et al. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14:64-78.
10. Ward N.S., Casserly B., Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 2008, 29:617-625.
11. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 136(5 Suppl):e28.
12. Boomer J.S., To K., Chang K.C., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
13. Skirecki T., Borkowska-Zielinska U., Zlotorowicz M., et al. Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances. Arch Immunol Ther Exp 2012, 60:123-135.
14. Rodrick M.L., Wood J.J., Grbic J.T., et al. Defective IL-2 production in patients with severe burns and sepsis. Lymphokine Res 1986, 5(Suppl 1):S75-S80.
15. MacNeil I.A., Suda T., Moore K.W., et al. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990, 145:4167-4173.
16. Frazier W.J., Hall M.W. Immunoparalysis and adverse outcomes from critical illness. Pediatr Clin North Am 2008, 55:647-668.
17. Allantaz-Frager F., Turrel-Davin F., Venet F., et al. Identification of biomarkers of response to IFNg during endotoxin tolerance: application to septic shock. PLoS One 2013, 8:e68218.
18. Monneret G., Venet F., Meisel C., et al. Assessment of monocytic HLA-DR expression in ICU patients: analytical issues for multicentric flow cytometry studies. Crit Care 2010, 14:432.
19. Guisset O., Dilhuydy M.S., Thiebaut R., et al. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med 2007, 33:148-152.
20. Puyana J.C., Pellegrini J.D., De A.K., et al. Both T-helper-1- and T-helper-2-type lymphokines are depressed in posttrauma anergy. J Trauma 1998, 44:1037-1045. [discussion 1045-46].
21. Schwacha M.G., Ayala A., Chaudry I.H. Insights into the role of gammadelta T lymphocytes in the immunopathogenic response to thermal injury. J Leukoc Biol 2000, 67:644-650.
22. Venet F., Filipe-Santos O., Lepape A., et al. Decreased T-cell repertoire diversity in sepsis: a preliminary study. Crit Care Med 2013, 41:111-119.
23. Letulzo Y., Pangault C., Gacouin A., et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002, 18:487-494.
24. Toliver-Kinsky T.E., Cui W., Murphey E.D., et al. Enhancement of dendritic cell production by fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection. J Immunol 2005, 174:404-410.
25. Hall M.W., Knatz N.L., Vetterly C., et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 2011, 37:525-532.
26. Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009, 30:475-487.
27. Monneret G., Lepape A., Voirin N., et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32:1175-1183.
28. Hall M.W., Geyer S.M., Guo C.Y., et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med 2013, 41:224-236.
29. Song G.Y., Chung C.S., Chaudry I.H., et al. What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant?. Surgery 1999, 126:378-383.
30. Venet F., Lepape A., Monneret G. Clinical review: flow cytometry perspectives in the ICU-from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit Care 2011, 15:231.
31. Zielinska-Borkowska U., Skirecki T., Zlotorowicz M., et al. Procalcitonin in early onset ventilator-associated pneumonia. J Hosp Infect 2012, 81:92-97.
32. Dahaba A.A., Hagara B., Fall A., et al. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006, 97:503-508.
33. Monneret G., Arpin M., Venet F., et al. Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils. Intensive Care Med 2003, 29:923-928.
34. Monneret G., Doche C., Durand, et al. Procalcitonin as a specific marker of bacterial infection in adults. Clin Chem Lab Med 1998, 36:67-68.
35. Toltl L.J., Swystun L.L., Pepler L., et al. Protective effects of activated protein C in sepsis. Thromb Haemost 2008, 100:582-592.
36. Toltl L.J., Beaudin S., Liaw P.C. Canadian Critical Care Translational Biology Group. Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J Immunol 2008, 181:2165-2173.
37. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. NEJM 2003, 348:138-150.
38. Turrel F., Guignant C., Venet F., et al. Innovative therapeutic strategies for restoring lymphocyte functions in septic patients. Inflamm Allergy Drug Targets 2008, 7:181-186.
39. Kreymann K.G., de Heer G., Nierhaus A., et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007, 35:2677-2685.
40. Ranieri V.M., Thompson B.T., Barie P.S., et al. Drotrecogin alfa (activated) in adults with septic shock. NEJM 2012, 366:2055-2064.
41. Rosenbloom A.J., Linden P.K., Dorrance A., et al. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 2005, 127:2139-2150.
42. Meisel C., Schefold J.C., Pschowski R., et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648.